Lupin could face FDA regulatory action over Tarapur API facility

13 Jan 2020

India’s Lupin Pharmaceuticals warned Monday it could face regulatory sanctions from the US Food and Drug Administration over its Tarapur active pharmaceutical ingredient (API) manufacturing facility.

“The company has received a communication from the US FDA classifying the inspection conducted at its Tarapur manufacturing (API) facility between September 16 to September 20, 2019 as Official Action Indicated,” Lupin said in a filing to the Bombay Stock Exchange.

Lupin could face FDA regulatory action over Tarapur API facility

According to the FDA’s official definition, an OIA means that “objectional conditions were found and regulatory administrative sanctions by FDA are indicated.”

Lupin said in the filing it did not believe that the inspection classification would have an impact on disruption of supplies or the existing revenues from operations of the facility.

“The company is in the process of sending further updates of its corrective actions to the US FDA and is hopeful of a positive outcome,” Lupin said.

Back in October, the FDA issued a Form 483 listing three observations of violations of current good manufacturing practices (cGMP) at the Tarapur plant.

In the letter, the FDA said Lupin had failed to maintain batch production and control records and not carried out a satisfactory review of unexplained discrepancies “whether or not the batch has already been distributed.”

The FDA also cited failure by workers at the plant “to handle and store cleaned utensils in a manner to prevent contamination.”

Separately in another exchange filing on January 11, Lupin said the FDA had completed a Prior Approval Inspection at its Nagpur oral solid dosage manufacturing facility between January 6 and January 10, closing with 483 observations.

Lupin managing director, Nilesh Gupta said the company was committed to meeting the highest quality standards and to full compliance with current good manufacturing practice regulations at all its manufacturing facilities.

“We will address the observations raised by the agency satisfactorily and will submit our comprehensive response within the stipulated timeline,” he added.

Related news

iNova Pharmaceuticals announces the launch of iPitch 2020

iNova Pharmaceuticals announces the launch of iPitch 2020

3 Jul 2020

Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.

Read more 
Ajinomoto introduces fast track platform for drug product manufacturing

Ajinomoto introduces fast track platform for drug product manufacturing

30 Jun 2020

AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.

Read more 
CPhI Worldwide to transform into Festival of Pharma digital experience

CPhI Worldwide to transform into Festival of Pharma digital experience

30 Jun 2020

The 10-day event will feature an interactive digital marketplace for sourcing products and services, enhanced matchmaking for connecting with new and existing partners, and world-renowned speakers.

Read more 
Catalent expands beauty and plant-based consumer health softgel capabilities

Catalent expands beauty and plant-based consumer health softgel capabilities

30 Jun 2020

Two company sites - one in Canada, the other in Brazil - receive new softgel encapsulation lines to service local customer demand.

Read more 
Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines

Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines

29 Jun 2020

The company agrees to provide CEPI with 100 million glass vials, which can store 20 doses per vial (2 billion doses in total).

Read more 
PCI Pharma Services completes biotech Center of Excellence

PCI Pharma Services completes biotech Center of Excellence

29 Jun 2020

The global outsourcing solutions provider is also set to expand its biotech capabilities in Europe.

Read more 
DuPont's seaweed-based soft capsule ingredient gains non-GMO certification

DuPont's seaweed-based soft capsule ingredient gains non-GMO certification

29 Jun 2020

SeaGel offers drug and dietary supplement manufacturers an animal-free and sustainable alternative to traditional soft capsules.

Read more 
Gilead pencils in potential buyout of Pionyr Immunotherapeutics

Gilead pencils in potential buyout of Pionyr Immunotherapeutics

23 Jun 2020

Pionyr's "promising, novel biology" could represent a major increase in Gileads's cancer pipeline.

Read more 
CordenPharma & Moderna extend lipid supply agreement for Moderna’s coronavirus vaccine

CordenPharma & Moderna extend lipid supply agreement for Moderna’s coronavirus vaccine

23 Jun 2020

The amended manufacturing agreement, which originally specified CordenPharma facilities Switzerland, now extends to the CDMOs France and US sites.

Read more 
TraceLink announces results from FDA DSCSA Pilot Program

TraceLink announces results from FDA DSCSA Pilot Program

23 Jun 2020

Key findings demonstrate the value of network solutions to secure and digitalize the pharmaceutical supply chain.

Read more